This study evaluated the efficacy of generic tyrosine kinase inhibitors (TKIs) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and analyzed Breakpoint Cluster Region-Abelson (BCR-ABL) kinase domain mutations in patients exhibiting TKI resistance. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.